

05-19-2003

Department of Commerce
Patent and Trademark Office
Docket No. 7203-4
Customer Number: 22,852
Patent Recordation Services

5-14-03

To the Director of the U.S. Patent and Trademark Office:
Please record the attached original documents or copy there...

102451475

1. Name of conveying party(ies):
CeNeS Limited

2. Name and address of receiving party(ies):

Name: Addex Pharmaceuticals, SA

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

Internal Address:

3. Nature of conveyance:

Street Address: 12, chemin des Aux
Plan les Ouates☒ Assignment ☐ Merger

City: Geneva

☐ Security Agreement ☐ Change of Name

Country: Switzerland Zip Code:

☐ Other:

Additional name(s) & Address(es) attached?

Execution Date: 12/18/02

☐ Yes ☒ No

4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application:

A. Patent Application Number(s):

B. Patent Number(s):

~~6,211,173~~ (formerly SN 09/380,840);
5,512,562, and 5,658,899

Additional numbers attached?

☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Arthur S. Garrett, Esq.

6. Total number of applications and registrations involved:
three

7. Total fee (37 CFR 3.41): \$120

☒ Enclosed (Please charge deficiency to deposit account)☐ Authorized to be charged to deposit accountInternal Address: FINNEGAN, HENDERSON, FARABOW, GARRETT
& DUNNER, L.L.P.

Street Address: 1300 I Street, N.W.

City: Washington, D.C.

State: Zip: 20005-3315

8. Deposit Account No.: 06-0916

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Arthur S. Garrett
Reg. No. 20,338

05/16/2003 DBYRNE 00000143 6211173

01 FC:0021

120.00 OP

Total number of pages including cover sheet, attachments and documents: 11

Signature

May 14, 2003

Date

Schedule 3

Form of assignment for registration

THIS ASSIGNMENT is dated 18 December 2002

BETWEEN:

- (1) CeNeS Limited a company incorporated in England with registered number 03078401 whose registered office is at Compass House, Vision Park, Chivers Way, Histon, Cambs CB4 42R (the "Assignor"); and
- (2) Addex Pharmaceuticals, SA. incorporated under the laws of Switzerland whose principal place of business is at 12, chemin des Anlx, Plan les Ouates, Geneva, Switzerland (the "Assignee")

WHEREAS:

- (A) By an agreement (the "Main Agreement") dated the same date as this Deed, and made between Assignor and Assignee, Assignor agreed, inter alia, to assign to Assignee the Patents and Patent Applications referred to in the Schedule hereto (together the "Patents").

NOW IT IS HEREBY AGREED as follows:

- I. In pursuance of and for the consideration set out in the Main Agreement Assignor hereby assigns to Assignee all property, right, title and interest in the Patents TO HOLD the same unto the Assignee absolutely.

IN WITNESS of which this Agreement has been executed as a deed and delivered the day and year first above written.

EXECUTED as a deed by CeNeS LIMITED)

acting by)

Neil Clark (Chief Operating Officer) and)

Terry Smith (Development Director))



.....
Director

.....
Director/Secretary

20/12/02 14:55 FAX 00227370099
20/12/02 13:27 FAX 0041228841556

INDEX
ADDEX PHARMACEUTICALS SA

003

005

FILE No. 430 18.12.'02 18:20 ID: CENES LIMITED

FAX: 01223266467

PAGE 3/ 5


EXECUTED as a deed by

ADDEX PHARMACEUTICALS, SA)

acting by)

Francois Conquet (Chief Executive Officer) and)

Richard Rimer (Non-Executive Director))



.....

Director

.....

Director/Secretary

Schedule 2

Patents and Applications

<i>R&G Ref</i>	Priority	Application No.	Reference	Countries	Status
39201.AU01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	66100/98 742873	Sleep Disorders (ex Novo Nordisk A/S)	AU	GRANTED
39201.BR01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	PI 9808234-5	Sleep Disorders (ex Novo Nordisk A/S)	BR	Pending
39201.CA01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	2,283,083	Sleep Disorders (ex Novo Nordisk A/S)	CA	Pending
39201.CZ01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	PV 3177-99	Sleep Disorders (ex Novo Nordisk A/S)	CZ	Pending

39201.EP01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	98907896.9	Sleep Disorders (ex Novo Nordisk A/S)	EP: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE	Lapsed
39201.HU01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	P0000679	Sleep Disorders (ex Novo Nordisk A/S)	HU	Pending
39201.IN01	DK 0265/97 12.03.97	496/MAS/98	Sleep Disorders (ex Novo Nordisk A/S)	IN	Pending - NB official confirmation of the recordal of the assignment will not happen until the application is examined and accepted.
39201.IL01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	313670	Sleep Disorders (ex Novo Nordisk A/S)	IL	Pending
39201.JP01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	10-539102 2001-515484	Sleep Disorders (ex Novo Nordisk A/S)	JP	Pending

39201.MX01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	998341	Sleep Disorders (ex Novo Nordisk A/S)	MX	Pending
39201.NO01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	19994343	Sleep Disorders (ex Novo Nordisk A/S)	NO	Pending
39201.PL01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	P335545	Sleep Disorders (ex Novo Nordisk A/S)	PL	Pending
39201.US01	DK 0265/97 12.03.97 US 60/041,509 24.3.97	09/380,840	Sleep Disorders (ex Novo Nordisk A/S)	US	Granted
39201.ZA01	DK 0265/97 12.03.97	98/1918	Sleep Disorders (ex Novo Nordisk A/S)	ZA	Granted
41921.AU01	DK 267/93 10.3.93	61386/94 682494	D1 Antagonist	AU	Granted
41921.CA01	DK 267/93 10.3.93	2,157,668	D1 Antagonist	CA	Pending

41921.CN01	DK 267/93 10.3.93	94191882.3	D1 Antagonist	CN	Granted
41921.EP01	DK 267/93 10.3.93	94908289.5 0 688 320	D1 Antagonist	EP: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	Granted
41921.FI01	DK 267/93 10.3.93	954229	D1 Antagonist	FI	Pending
41921.IL01	DK 267/93 10.3.93	108730	D1 Antagonist	IL	Granted
41921.JP01	DK 267/93 10.3.93	6-519470	D1 Antagonist	JP	Pending
41921.NZ01	DK 267/93 10.3.93	262098	D1 Antagonist	NZ	Granted
41921.TW01	DK 267/93 10.3.93	83101509 079660	D1 Antagonist	TW	Granted
41921.US01	DK 267/93 10.3.93	08/202,401 5,512,562	D1 Antagonist	US	Granted
41921.ZA01	DK 267/93 10.3.93	94/1377	D1 Antagonist	ZA	Granted
41922.EP01	DK 0311/94 16.03.94	95912143.5 0 750 616	NNC 22- 0010	EP: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LU, MC, NL, SE	Granted

41922.US01	DK 0311/94 16.03.94	404,394 5,658,889	NNC 22- 0010	US	Granted
41929.AT01	DK 3251/88 15.06.88	347672	NNC 01- 687	AT	Granted
41929.AU01	DK 3251/88 15.06.88	622911	NNC 01- 687	AU	Granted
41929.BE01	DK 3251/88 15.06.88	347672	NNC 01- 687	BE	Granted
41929.CA01	DK 3251/88 15.06.88	1317938	NNC 01- 687	CA	Granted
41929.CH01	DK 3251/88 15.06.88	347672	NNC 01- 687	CH	Granted
41929.DK01	DK 3251/88 15.06.88	163993	NNC 01- 687	DK	Granted

41929.DE01	DK 3251/88 15.06.88	68913367.7	NNC 01-687	DE	Granted
41929.ES01	DK 3251/88 15.06.88	347672	NNC 01-687	ES	Granted
41929.FI01	DK 3251/88 15.06.88	93354	NNC 01-687	FI	Granted
41929.FR01	DK 3251/88 15.06.88	347672	NNC 01-687	FR	Granted
41929.GB01	DK 3251/88 15.06.88	347672	NNC 01-687	GB	Granted
41929.GR01	DK 3251/88 15.06.88	3012025	NNC 01-687	GR	Granted
41929.IE01	DK 3251/88 15.06.88	64965	NNC 01-687	IE	Granted

41929.IL01	DK 3251/88 15.06.88	90533	NNC 01- 687	IL	Granted
41929.IT01	DK 3251/88 15.06.88	347672	NNC 01- 687	IT	Granted
41929.JP01	DK 3251/88 15.06.88	2769718	NNC 01- 687	JP	Granted
41929.LU01	DK 3251/88 15.06.88	347672	NNC 01- 687	LU	Granted
41929.NL01	DK 3251/88 15.06.88	347672	NNC 01- 687	NL	Granted
41929.NO01	DK 3251/88 15.06.88	173865	NNC 01- 687	NO	Granted
41929.NZ01	DK 3251/88 15.06.88	229521	NNC 01- 687	NZ	Granted

41929.PT01	DK 3251/88 15.06.88	90883	NNC 01- 687	PT	Granted
41929.SE01	DK 3251/88 15.06.88	347672	NNC 01- 687	SE	Granted
41929.US01	DK 3251/88 15.06.88	5010074	NNC 01- 687	US	Granted
41929.US02	DK 3251/88 15.06.88	5025009	NNC 01- 687	US	Granted
41929.ZA01	DK 3251/88 15.06.88	89/4427	NNC 01- 687	ZA	Granted